Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 25%Very low 0 · 0%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Adverse events: all grades · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.99 [0.74, 1.31]
1 study · 243 participants
Low

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
OR 4
3 participants
GRADE not reported

Hyperimmune immunoglobulin from human plasma vs saline placebo

Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate

Hyperimmune immunoglobulin from human plasma vs saline placebo

Adverse events: all grades · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.98 [0.81, 1.18]
Studies not reported
Low